Psoriasis is a chronic inflammatory disease triggered by both genetic and environmental factors. Systemic and biologic therapies used to treat moderate-to-severe psoriasis show significant variability in efficacy, are associated with various degrees of toxicity, and, for biologic therapies, are expensive. There is a great need for non-invasive biomarkers to predict treatment outcomes of these therapies and to individualize care for patients with psoriasis. This article reviews currently recognized pharmacogenetic targets related to the treatment of chronic plaque psoriasis, in particular to biologic therapies. The use of pharmacogenetic and pharmacogenomic approaches to genetically profile patients will allow therapies to be targeted more precisely and safely to individual patients, to optimize the treatment of psoriasis, and minimize unnecessary costs. Characterizing patients with psoriasis according to common molecular mechanisms rather than by clinical phenotype may also allow more selective therapeutic agents to be targeted to genetically distinct groups of patients.

Talamonti, M., D'Adamio, S., Bianchi, L., & Galluzzo, M. (2017). The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature. MOLECULAR DIAGNOSIS & THERAPY [10.1007/s40291-017-0274-z].

The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature

Talamonti, M;BIANCHI, LUCA;Galluzzo, M.
2017

Abstract

Psoriasis is a chronic inflammatory disease triggered by both genetic and environmental factors. Systemic and biologic therapies used to treat moderate-to-severe psoriasis show significant variability in efficacy, are associated with various degrees of toxicity, and, for biologic therapies, are expensive. There is a great need for non-invasive biomarkers to predict treatment outcomes of these therapies and to individualize care for patients with psoriasis. This article reviews currently recognized pharmacogenetic targets related to the treatment of chronic plaque psoriasis, in particular to biologic therapies. The use of pharmacogenetic and pharmacogenomic approaches to genetically profile patients will allow therapies to be targeted more precisely and safely to individual patients, to optimize the treatment of psoriasis, and minimize unnecessary costs. Characterizing patients with psoriasis according to common molecular mechanisms rather than by clinical phenotype may also allow more selective therapeutic agents to be targeted to genetically distinct groups of patients.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - Malattie Cutanee e Veneree
English
Talamonti, M., D'Adamio, S., Bianchi, L., & Galluzzo, M. (2017). The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature. MOLECULAR DIAGNOSIS & THERAPY [10.1007/s40291-017-0274-z].
Talamonti, M; D'Adamio, S; Bianchi, L; Galluzzo, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Galluzzo- The Role of Pharmacogenetics in Chronic Plaque Psoriasis Update of the Literature.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 668.8 kB
Formato Adobe PDF
668.8 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/185038
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact